Home/Filings/4/0001479290-21-000171
4//SEC Filing

Rankin Aubrey 4

Accession 0001479290-21-000171

CIK 0001479290other

Filed

Dec 5, 7:00 PM ET

Accepted

Dec 6, 8:34 PM ET

Size

6.9 KB

Accession

0001479290-21-000171

Insider Transaction Report

Form 4
Period: 2021-12-03
Rankin Aubrey
DirectorPresident, Innovation & Tech
Transactions
  • Purchase

    Common Stock

    2021-12-03$14.43/sh+30,000$432,87695,463 total
Holdings
  • Common Stock

    (indirect: By Trust)
    154,302
  • Common Stock

    (indirect: By Trust)
    321,611
Footnotes (3)
  • [F1]The price reported in Table 1, Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $14.33 to $14.50. Mr. Rankin undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
  • [F2]These shares are held by The Rankin Irrevocable Trust. Mr. Rankin is a Trustee of the Rankin Irrevocable Trust.
  • [F3]These shares are held by the Aubrey and Luanne Rankin Revocable Living Trust dated July 1, 2009. Mr. Rankin is a Trustee of this Trust.

Issuer

Revance Therapeutics, Inc.

CIK 0001479290

Entity typeother

Related Parties

1
  • filerCIK 0001818576

Filing Metadata

Form type
4
Filed
Dec 5, 7:00 PM ET
Accepted
Dec 6, 8:34 PM ET
Size
6.9 KB